Who
Anne Lesage
Chief Early Development
Company insider
Files Form 4 as: Chief Early Development, Pharvaris.
In numbers
- Trades disclosed
- 96
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $13.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 22 Apr 2026
- Last trade
- 17 Sep 2026
- Last filed
- 21 Sep 2026
Companies traded
Activity over time
1 Apr – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Sep 2026filed 21 Sep 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $765K20,000 at $38.27 | filing |
| 17 Sep 2026filed 21 Sep 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $765K20,000 at $38.27 | filing |
| 10 Sep 2026filed 14 Sep 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Code M | $242K30,000 at $8.05 | filing |
| 10 Sep 2026filed 14 Sep 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $1.1M30,000 at $38.30 | filing |
| 10 Sep 2026filed 14 Sep 2026 | PHVS Pharvarisoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,000 at $0.00 | filing |
| 10 Sep 2026filed 14 Sep 2026 | PHVS Pharvarisoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,000 at $0.00 | filing |
| 10 Sep 2026filed 14 Sep 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Code M | $242K30,000 at $8.05 | filing |
| 10 Sep 2026filed 14 Sep 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $1.1M30,000 at $38.30 | filing |
| 30 Jun 2026filed 1 Jul 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $1.1M30,703 at $35.49 | filing |
| 30 Jun 2026filed 1 Jul 2026 | PHVS Pharvarisoption or derivative · Biotechnology | SEC FORM 4 Code M | —24,900 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | PHVS Pharvarisoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,972 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | PHVS Pharvarisoption or derivative · Biotechnology | SEC FORM 4 Code M | —24,900 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | PHVS Pharvarisoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,972 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Code M | $7,6972,972 at $2.59 | filing |
| 30 Jun 2026filed 1 Jul 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Code M | $200K24,900 at $8.05 | filing |
| 30 Jun 2026filed 1 Jul 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $989K27,872 at $35.48 | filing |
| 30 Jun 2026filed 1 Jul 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Code M | $7,6972,972 at $2.59 | filing |
| 30 Jun 2026filed 1 Jul 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Code M | $200K24,900 at $8.05 | filing |
| 30 Jun 2026filed 1 Jul 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $989K27,872 at $35.48 | filing |
| 30 Jun 2026filed 1 Jul 2026 | PHVS PharvarisBiotechnology | SEC FORM 4 Sold | $1.1M30,703 at $35.49 | filing |
News
No headline names them, or the companies they trade most, lately.